Despite the encouraging therapeutic effects of immune checkpoint inhibitors against PD-1, PD-L1, and CTLA-4 across multiple tumor types, the prognosis of metastatic PCa remains unsatisfactory mainly because of drug resistance [32]. The gene discussed is PDCD1; the disease is posterior cortical atrophy.